December 08, 2019
Article
Complete remissions were achieved in greater than 20% of patients with highly refractory non-Hodgkin lymphomas who had been previously been treated with chimeric antigen receptor T-cell therapy with Mosunetuzumab, a novel bispecific antibody, according to study results presented at the 2019 American Society of Hematology Annual Meeting.
June 02, 2019
Article
The treatment of EGFR-mutant non–small cell lung cancer has experienced significant improvements with the development of tyrosine kinase inhibitors, but resistance mechanisms that promote disease recurrence have tampered the runaway success of these revolutionary agents, said Katerina A. Politi, PhD, during the 2019 ASCO Annual Meeting. Early findings are presented for 2 novel agents aiming to potentially overcome resistance.
November 12, 2016
Article
A new immune checkpoint called PVRIG has emerged as a ripe target for anticancer therapy in solid tumors and an antibody that blocks its ability to suppress an antitumor response is in development.